BioSpace

Boehringer bets big on China, offering $7B biobucks for Sino cancer programs

Boehringer Ingelheim is building up its China strategy, inking a deal to develop new cancer treatments with Sino Biopharmaceutical just weeks after opening an R&D facility in Shanghai.

By BioSpace

1 min read
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights